Lack of NMDA receptor involvement in caffeine-induced locomotor stimulation and tolerance in rats

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 2, 1998, Pages 433-438

  Powell, Kelly R ^a   Holtzman, Stephen G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Caffeine; Locomotor activity; MK 801; NMDA; Phencyclidine; Rats; Tolerance

Indexed keywords

CAFFEINE; DIZOCILPINE; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRINKING; DRUG EFFECT; DRUG TOLERANCE; LOCOMOTION; MALE; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; STIMULATION;

ANIMALS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; STIMULATION, CHEMICAL; TIME FACTORS;

EID: 0032006538     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00447-4     Document Type: Article

References (42)

1. Ahlijanian M. K., Takemori A. E. Cross-tolerance studies between caffeine and (-)-N6(phenylisopropyl)adenosine (PIA) in mice. Life Sci. 38:1986;577-588.
2. Amalric M., Ouagazzal A., Baunez C., Nieoullon A. Functional interactions between glutamate and dopamine in the rat striatum. Neurochem. Int. 25:1994;123-231.
3. Clineschmidt B. V., Martin G. E., Bunting P. R., Papp N. L. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties. Drug Dev. Res. 2:1982;135.
4. Daly J. W., Bruns R. F., Snyder S. H. Adenosine receptors in the central nervous system. Relationship to the central actions of methylxanthines Life Sci. 28:1981;2083-2097.
5. 3H-SCH23390 from rat striatum membranes. Eur. J. Pharmacol. 179:1990;295-299.
6. Ferre S., Herrera-Marschitz M., Grabowska-Anden M., Casas M., Ungerstedt U., Anden N.-E. Postsynaptic dopamine/adenosine interaction. II. Postsynaptic dopamine agonism and adenosine antagonism of the methylxanthines in short-term reserpinized mice Eur. J. Pharmacol. 192:1991;31-37.
7. 2 receptors in the rat striatal membranes. Proc. Natl. Acad. Sci. USA. 88:1991;7238-7241.
8. Ferre S., O'Connor W. T., Fuxe K., Ungerstedt U. The striopallidal neuron. A main locus for adensosine-dopamine interactions in the brain J. Neurosci. 13:1993;5402-5406.
9. 1 receptors. Neuroreport. 6:1994;73-76.
10. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience. 63:1994;765-773.
11. 1 receptor antagonist binding sites Neurosci. Lett. 208:1996;109-112.
12. Finn I. B., Holtzman S. G. Tolerance to caffeine-stimulation of locomotor activity in rats. J. Pharmacol. Exp. Ther. 238:1986;542-546.
13. Finn I. B., Holtzman S. G. Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, d-amphetamine, and methylphenidate. Neuropharmacology. 29:1990;625-631.
14. 2 dopamine receptor antagonists block caffeine-induced stimulation of locomotor activity in rats. Pharmacol. Biochem. Behav. 47:1994;89-94.
15. 2 receptor agonists but not to their synergistic interaction. Eur. J. Pharmacol. 262:1994;65-75.
16. Gimenez-Llort L., Martinez E., Ferre S. Dopamine-independent and adenosine-dependent mechanisms involved in the effects of N-methyl-d-aspartate on motor activity in mice. Eur. J. Pharmacol. 275:1995;171-177.
17. Griffiths R. R., Mumford G. K. Caffeine. A drug of abuse? Bloom F. E., Kupfer D. J. Psychopharmacology. The fourth generation of progress:1995;1699-1713 Raven Press, New York.
18. Hawkins M., Dugich M. M., Porter N. M., Urbancic M., Radulovacki M. Effects of chronic administration of caffeine on adenosine A1 and A2 receptors in rat brain. Brain Res. Bull. 21:1988;479-482.
19. Hoffman D. C. Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J. Neural Transm. 89:1992;1-10.
20. Holtzman S. G. Complete, reversible drug-specific tolerance to stimulation of locomotor-activity by caffeine. Life Sci. 33:1983;779-787.
21. Holtzman S. G., Finn I. B. Tolerance to behavioral effects of caffeine in rats. Pharmacol. Biochem. Behav. 29:1988;411-418.
22. Holtzman S. G., Mante S., Minneman K. P. Role of adenosine receptors in caffeine tolerance. J. Pharmacol. Exp. Ther. 256:1991;62-68.
23. Johansson B., Ahlberg S., van der Ploeg I., Brene S., Lindefors N., Persson H., Fredholm B. B. Effect of long term caffeine treatment on A1 and A2 adenosine receptor binding and on mRNA levels in rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 347:1993;407-414.
24. Kaplan G. B., Greenblatt D. J., Kent M. A., Cotreau M. M., Arcelin G, Shader R. I. Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology. 6:1992;145-153.
25. Kalivas P. W., Alesdatter J. E. Involvement of NMDA receptor stimulation in the VTA and amygdala in behavioral sensitization. J. Pharmacol. Exp. Ther. 267:1993;486-495.
26. Karler R., Calder L. D., Chaudhry I. A., Turkanis S. A. Blockade of "reverse tolerance" to cocaine and amphetamine by MK-801. Life Sci. 45:1989;599-606.
27. Kirch D. G., Taylor T. R., Gerhardt G. A., Benowitz N. L., Stephen C., Wyatt R. J. Effect of chronic caffeine administration on monoamine and monoamine metabolite concentrations in rat brain. Neuropharmacology. 29:1990;599-602.
28. Kuribara H., Asami T., Ida I., Tadokoro S. Characteristics of the ambulation-increasing effect of the noncompetitive NMDA antagonist MK-801 in mice. Assessment by the coadministration with central-acting drugs Jpn. J. Pharmacol. 58:1992;11-18.
29. Morgan M. E., Vestal R. E. Methylxanthine effects on caudate dopamine release as measured by in vivo electrochemistry. Life Sci. 45:1989;2025-2039.
30. Ogren S. O., Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology. 11:1994;167-177.
31. 2 receptor blockade on MK-801-induced hyperlocomotion in rats. Psychopharmacology (Berlin). 111:1993;427-434.
32. Ouagazzal A.-M., Nieoullon A., Amalric M. Locomotor activation induced by MK-801 in the rat. Postsynaptic interactions with dopamine receptors in the ventral striatum Eur. J. Pharmacol. 251:1994;229-236.
33. Pulvirenti L., Swerdlow N. R., Koob G. F. Microinjection of a glutamate antagonist into the nucleus accumbens reduces psychostimulant locomotion in rats. Neurosci. Lett. 103:1989;213-218.
34. Pulvirenti L., Swerdlow N. R., Koob G. F. Nucleus accumbens NMDA antagonist decreases locomotor activity produced by cocaine, heroin or accumbens dopamine, but not caffeine. Pharmacol. Biochem. Behav. 40:1991;841-845.
35. Shoaib M., Benwell M. E., Akbar M. T., Stolerman I. P., Balfour B. J. Behavioral and neurochemical adaptations to nicotine in rats. Influence of NMDA antagonists Br. J. Pharmacol. 111:1994;1073-1080.
36. Snyder S. H., Katims J. J., Annau A., Bruns R. F., Daly J. W. Adenosine receptors and the behavioral actions of methylxanthines. Proc. Natl. Acad. Sci. USA. 78:1981;3260-3264.
37. Snyder S. H., Sklar P. Behavioral and molecular actions of caffeine. Focus on adenosine J. Psychiatr. Res. 18:1984;91-106.
38. Trujillo K. A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
39. Trujillo K. A., Akil H. Inhibition of opiate tolerance by noncompetitve N-methyl-D-aspartate receptor antagonists. Brain Res. 633:1994;178-188.
40. Watanabe H., Uramoto H. Caffeine mimics dopamine receptor agonists without stimulation of dopamine receptors. Neuropharmacology. 25:1986;577-581.
41. Witkin J. M. Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists. Life Sci. 53:1993;PL405-PL410.
42. Wolf M. E., White F. J., Hu X. T. MK-801 prevents alterations in the mesoaccumbens dopamine system associated with behavioral sensitization to amphetamine. J. Neurosci. 14:1994;1735-1745.